Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT – Get Free Report) was the recipient of a significant decline in short interest during the month of May. As of May 15th, there was short interest totaling 18,505 shares, a decline of 97.7% from the April 30th total of 802,992 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 318,127 shares, the days-to-cover ratio is presently 0.1 days.
Provectus Biopharmaceuticals Price Performance
Provectus Biopharmaceuticals stock remained flat at $0.07 during mid-day trading on Friday. 66,703 shares of the company’s stock traded hands, compared to its average volume of 281,354. Provectus Biopharmaceuticals has a one year low of $0.04 and a one year high of $0.11. The business has a 50-day moving average of $0.06 and a two-hundred day moving average of $0.06.
About Provectus Biopharmaceuticals
Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.
PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.
Featured Stories
- Five stocks we like better than Provectus Biopharmaceuticals
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for Provectus Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
